Stock Details
AZN is AstraZeneca PLC's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 62.22$. Average daily volumn in 3 months 6.46M. Market cap 172.48B



Stock symbol : AZN. Exchange : NasdaqGS. Currency : USD
Lastest price : 56.73$. Total volume : 9.26M. Market state POST
Click reload if you want to check the lastest price on market!!!

AstraZeneca PLC (AZN)
Last Price
56.73$
Change
-0.31
Volume
9.26M

Previous Close57.04
Open56.05
Day Range55.99-56.91
Bid56.35 x 3.2k
Ask56.72 x 1.1k
Volume9.26M
Average Volume6.46M
Market Cap172.48B
Beta0.13
52 Week Range52.65-71.70
Trailing P/EN/A
Foward P/E15.59
Dividend (Yield %)2.64%
Ex-Dividend Date2022-08-11



Financial Details


According to AstraZeneca PLC's financial reports the company's revenue in 2021 were 37.42B an increase( +42.31%) over the years 2020 revenue that were of 26.62B. In 2021 the company's total earnings were 112M while total earnings in 2020 were 3.2B(-96.27%).


Loading ...



Organization

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolis... m diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Cap:
172.48B
Revenue:
37.42B
Total Assets:
105.36B
Total Cash:
6.33B


News about "AstraZeneca PLC"

astrazeneca-acquires-local-startup-at-660-premium-image

AstraZeneca acquires local startup at 660% premium

Source from : The Business Journals - 2 days ago

AstraZeneca Rare Disease, the local division AstraZeneca formed when it acquired Alexion Pharmaceuticals Inc. last year, has scooped up a struggling local biotech at a significant premium.See details»


geneos-wealth-management-inc-sells-440-shares-of-astrazeneca-plc-nasdaqazn-image

Geneos Wealth Management Inc. Sells 440 Shares of AstraZeneca PLC (NASDAQ:AZN)

Source from : Defense World - 18 hours ago

Geneos Wealth Management Inc. lowered its stake in AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) by 3.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities ...See details»


astrazeneca-plc-nasdaqazn-shares-sold-by-sandy-spring-bank-image

AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Sandy Spring Bank

Source from : Defense World - 1 days ago

Bank reduced its position in AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) by 13.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The ...See details»


astrazeneca-throws-lifeline-to-gene-editing-biotech-logicbio-with-68m-buyout-image

AstraZeneca throws lifeline to gene-editing biotech LogicBio with $68M buyout

Source from : MedCity News - 2 days ago

AstraZenecaโ€™s LogicBio acquisition comes at a critical time for the biotech. Though LogicBio has encouraging early clinical data for its lead gene-editing therapeutic candidate, the companyโ€™s cash ...See details»


ADRs End Higher, ABB and AstraZeneca Trade Actively

Source from : MarketWatch - 2 days ago

By Denny Jacob International stocks trading in New York closed higher Monday. The S&P/BNY Mellon index of American depositary receipts edged up 2.6% ...See details»


AstraZeneca to Buy LogicBio Therapeutics for $68 Million >LOGC

Source from : MarketWatch - 2 days ago

By Colin Kellaher LogicBio Therapeutics Inc. on Monday said it agreed to be acquired by AstraZeneca PLC for about $68 million in a deal supporting ...See details»


astrazeneca-covid-19-antibodies-unlikely-to-protect-against-new-omicron-subvariant-image

AstraZeneca COVID-19 antibodies unlikely to protect against new Omicron subvariant

Source from : Seeking Alpha - 2 days ago

The FDA warned healthcare providers Monday that the fast-spreading Omicron subvariant BA.4.6 could be less susceptible to monoclonal antibodies tixagevimab and cilgavimab ...See details»


astrazeneca-pays-660-premium-for-gene-therapy-firm-logicbio-image

AstraZeneca pays 660% premium for gene therapy firm LogicBio

Source from : Reuters on MSN - 2 days ago

Shares of LogicBio Therapeutics skyrocketed on Monday after Britain's AstraZeneca's said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.See details»


astrazeneca-to-acquire-gene-editing-biotech-logicbio-image

AstraZeneca to acquire gene editing biotech LogicBio

Source from : BioPharma Dive - 2 days ago

Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600%.See details»


LogicBio Therapeutics Shares Soar on Takeover by AstraZeneca

Source from : Morningstar%2c Inc. - 2 days ago

Shares of LogicBio Therapeutics Inc. skyrocketed Monday after the genetic-medicine company agreed to be acquired by Anglo-Swedish pharma giant's AstraZeneca PLC for more than 7.5 times Friday's ...See details»


AstraZeneca gets its third regulatory green light in a matter of weeks for asthma drug

Source from : Proactive Investors - 8 days ago

The treatment has been approved in Japan for severe bronchial asthma where high-dose traditional corticosteroids donโ€™t work AstraZeneca PLC (LSE:AZN) said its Tezspire treatment was approved ...See details»


zackscom-featured-highlights-include-coca-cola-general-dynamics-astrazeneca-boise-cascade-and-insperity-image

Zacks.com featured highlights include Coca-Cola, General Dynamics, AstraZeneca, Boise Cascade and Insperity

Source from : YAHOO!Finance - 2 days ago

Coca-Cola, General Dynamics, AstraZeneca, Boise Cascade and Insperity have been highlighted in this Screen of The Week article.See details»


Board Committee Changes

Source from : London South East - 5 days ago

AstraZeneca PLC today announced the appointment of Sheri McCoy, Non-Executive Director, as Chair of the Remuneration Committee. Sheri has served as a member of the Remuneration Committee since ...See details»


astrazeneca-buying-lexington-gene-therapy-firm-logicbio-for-70m-image

AstraZeneca buying Lexington gene therapy firm LogicBio for $70m

Source from : The Boston Globe on MSN - 2 days ago

The drug giant, which is expanding in Cambridge, will pay a huge stock premium for the struggling gene therapy firm ...See details»